Related Experiment Video
Updated: Jun 22, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Advances in the integration of drug metabolism into the lead optimization paradigm
1Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. walter.korfmacher@spcorp.com
Abstract:
The lead optimization paradigm includes a team of experts that has a multitude of parameters to consider when moving from an initial lead compound through the lead optimization phase to the development phase. While in the past the team may have had only a medicinal chemist and a pharmacologist, the current team would often include experts in the areas of drug metabolism and pharmacokinetics (DMPK) as well as chemical toxicity. This review provides an overview of the some of the recent advances in the areas of DMPK screening plus a discussion of some of the assays that can be used to begin to screen for toxicity issues. The focus of this review is the major potential problem areas: oral bioavailability, half-life, drug-drug interactions and metabolism and toxicity issues.
Related Concept Videos
Drug Discovery: Overview
Pharmacogenetics of Drug Metabolism: Overview
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Drug Biotransformation: Overview
Drug Biotransformation: Overview
Prodrugs
Prodrugs help overcome...